Otsuka Can't Duck Antitrust Claims Over Antipsychotic Drug

Law360, New York (August 29, 2016, 6:12 PM EDT) -- A New Jersey federal judge has ruled that Otsuka Pharmaceutical Co. Ltd. can’t duck antitrust counterclaims by generics maker Apotex Corp. in an infringement suit over patents related to the antipsychotic drug Abilify, but agreed to split the case and hear the infringement claims first.

U.S. District Judge Jerome B. Simandle held that Apotex has made a sufficient counterargument that Otsuka holds and has exerted monopoly power in the market for aripiprazole, an ingredient in Abilify, to overcome Otsuka’s bid to dismiss the claims, according to his opinion. But the judge also granted Otsuka’s alternative bid to bifurcate and stay the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS